摘要
目的观察与评价替雷利珠联合白蛋白紫杉醇对晚期肺癌患者血清miR-498、miR-1269、IP-10水平与对免疫能力的影响。方法回顾性分析2020年3月—2021年3月于该院进行肺癌治疗的晚期患者100例为研究对象,按不同治疗方案分为对照组和观察组,各50例。对照组采用白蛋白紫杉醇治疗模式,观察组接受替雷利珠联合白蛋白紫杉醇治疗模式。记录二组患者的血清miR-498、miR-1269、IP-10水平的变化,观察临床疗效及分析疗效相关指标。结果治疗后,二组患者的CD4^(+)、CD4^(+)/CD8^(+)均升高,CD8^(+)均降低,且观察组相比对照组差异更为显著(P<0.05)。通过治疗后,观察组患者的血清miR-498、miR-1269、IP-10下降水平更低,差异有统计学意义(P<0.05)。二组并发症发生率比较差异无统计学意义(P>0.05);观察组疾病控制率(DCR)明显高于对照组(P<0.05)。逻辑回归分析表明血清miR-498、miR-1269、IP-10水平和免疫能力均与临床疗效显著相关,且ROC曲线分析表明各指标均可以准确地评估疗效。结论晚期肺癌患者给予替雷利珠联合白蛋白紫杉醇治疗,血清miR-498、miR-1269、IP-10水平和免疫功能都得到了良好改善,其控制癌症症状效果显著,可有效提高患者临床疗效。
Objective To observe and evaluate the effect of tislelizumab combined with albumin paclitaxel on serum levels of miR-498,miR-1269 and IP-10 and immune capacity in patients with advanced lung cancer.Methods A retrospective analysis was conducted on one hundred late stage patients who underwent lung cancer treatment in our hospital from March 2020 to March 2021.They were divided into control group and observation group of 5o patients according to different treatment plans.The control group received albumin paclitaxel treatment mode,while the observation group received tirelizumab combined with albumin paclitaxel treatment mode.Record the changes in serum miR-498,miR-1269,and IP-10 levels of two groups of patients,observe their clinical efficacy,and analyze efficacy related indicators.Results After treatment,the CD4^(+),CD4^(+)/CD8^(+)in two groups were increased,CD8^(+)was decreased,and the difference between observation group and control group was more evident(P<0.05).After treatment,the serum levels of miR-498,miR-1269 and IP-10 in observation group were lower,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).The disease control rate(DCR)in observation group was significantly higher than that in control group(P<0.05).Logistic regression analysis showed that serum miR-498,miR-1269,IP-10 levels and immune capacity were obviously correlated with clinical efficacy,and ROC curve analysis showed that each index could accu-rately evaluate the efficacy.Conclusion Patients with advanced lung cancer were treated with tislelizumab combined with albumin paclitaxel,and serum miR-498,miR-1269 and IP-10 levels were well improved,which has a significant effect in controlling cancer symptoms,can effectively improve the clinical efficacy of patients,and is worthy of popularization and application.
作者
贾瑞
王超
李健
JIA Rui;WANG Chao;LI Jian(Department of Thoracic Surgery,First Hospital of Qinhuangdao,Qinhuangdao 066000,China)
出处
《中国煤炭工业医学杂志》
2023年第5期466-473,共8页
Chinese Journal of Coal Industry Medicine
基金
河北省医学科学研究课题计划编号(编号:20201152)
秦皇岛市科学技术研究与发展计划项目(编号:202004A103)。
